Site-specific drug-releasing polypeptide nanocarriers based on dual-pH response for enhanced therapeutic efficacy against drug-resistant tumors

Theranostics

Volumn 5, Issue 8, 2015, Pages 890-904

  Dong, Yaqiong ^a,b   Yang, Jun ^a   Liu, Hongmei ^a,c   Wang, Tianyou ^d   Tang, Suoqin ^e   Zhang, Jinchao ^b   Zhang, Xin ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b HEBEI UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d CAPITAL INSTITUTE OF PEDIATRICS   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Combination cancer therapy; Drug resistance; Dual pH response; Polypeptide nanocarriers; Site specific releasing

Indexed keywords

COMBRETASTATIN A4; DOXORUBICIN; MACROGOL; NANOCARRIER; POLYASPARTIC ACID; POLYHISTIDINE; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; DRUG CARRIER; PEPTIDE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER CELL LINE; CELL PH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NANOENCAPSULATION; NONHUMAN; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOLECULAR MEDICINE; NEOPLASMS; PH; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MICE, INBRED BALB C; MICE, INBRED ICR; MOLECULAR MEDICINE; NEOPLASMS; PEPTIDES; STILBENES;

EID: 84941275709     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11821     Document Type: Article

References (35)

1. He QJ, Shi JL. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater. 2014; 26: 391-411.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-34.
3. Kuo WS, Ku YC, Sei HT, Cheng FY, Yeh CS. Paclitaxel-loaded stabilizer-free poly(D, L-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anti-cancer drug resistance and cancer cellular imaging. J Chin Chem Soc-Taip. 2009; 56: 923-34.
4. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 2007; 27: 1375.
5. Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Tar. 2013; 13: 326-46.
6. Wan CPL, Letchford K, Jackson JK, Burt HM. The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. Int J Nanomed. 2013; 8: 379-91.
7. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliver Rev. 2011; 63: 623-39.
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
9. Zhang QB, Bindokas V, Shen JK, Fan HL, Hoffman RM, Xing HR. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther. 2011; 10: 1173-84.
10. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64: 3731-6.
11. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials. 2010; 31: 7115-23.
12. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2002; 83: 21-38.
13. Xu B, Shi PC, Fombon IS, Zhang YY, Huang F, Wang WG, et al. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cell Mol Dis. 2011; 47: 264-9.
14. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release. 2003; 91: 103-13.
15. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Edit. 2003; 42: 4640-3.
16. Rihova B, Etrych T, Sirova M, Kovar L, Hovorka O, Kovar M, et al. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl) methacrylamide copolymers through an amide or hydrazone bond. Mol Pharmaceut. 2010; 7: 1027-40.
17. Lin W, Kim D. pH-sensitive micelles with cross-linked cores formed from polyaspartamide derivatives for drug delivery. Langmuir. 2011; 27: 12090-7.
18. Lee ES, Shin HJ, Na K, Bae YH. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release. 2003; 90: 363-74.
19. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chem. 2005; 16: 122-30.
20. Urry DW, Peng SQ, Gowda DC, Parker TM, Harris RD. Comparison of Electrostatic-Induced and Hydrophobic-Induced Pka Shifts in Polypentapeptides-the Lysine Residue. Chem Phys Lett. 1994; 225: 97-103.
21. Zhang LF, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. Acs Nano. 2008; 2: 1696-702.
22. Sengupta S, Eavarone D, Capila I, Zhao GL, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005; 436: 568-72.
23. Tang HY, Yin LC, Lu H, Cheng JJ. Water-soluble poly(L-serine)s with elongated and charged side-chains: synthesis, conformations, and cell-penetrating properties. Biomacromolecules. 2012; 13: 2609-15.
24. Yin LC, Song ZY, Kim KH, Zheng N, Gabrielson NP, Cheng JJ. Non-viral gene delivery via membrane-penetrating, mannose-targeting supramolecular self-assembled nanocomplexes. Adv Mater. 2013; 25: 3063-70.
25. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6: 815-23.
26. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO(2) gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997; 3: 177-82.
27. Zhao ZL, Meng HM, Wang NN, Donovan MJ, Fu T, You MX, et al. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery. Angew Chem Int Edit. 2013; 52: 7487-91.
28. Wang YG, Yang TY, Wang X, Dai WB, Wang JC, Zhang XA, et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release. 2011; 149: 299-306.
29. Duan XP, Xiao JS, Yin Q, Zhang ZW, Yu HJ, Mao SR, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. Acs Nano. 2013; 7: 5858-69.
30. Yuan YY, Mao CQ, Du XJ, Du JZ, Wang F, Wang J. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv Mater. 2012; 24: 5476-80.
31. Ma JS, Cai JZ, Lin GY, Chen HL, Wang XQ, Wang XC, et al. Development of LC-MS determination method and back-propagation ANN pharmacokinetic model of corynoxeine in rat. J Chromatogr B. 2014; 959: 10-5.
32. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garciakendall D. Antineoplastic agents. 145. Isolation and structure of the strong cell-growth and tubulin inhibitor combretastatin-a-4. Experientia. 1989; 45: 209-11.
33. Mcgown AT, Fox BW. Differential cytotoxicity of combretastatin-A1 and combretastatin-A4 in 2 daunorubicin-resistant P388 cell-lines. Cancer Chemoth Pharm. 1990; 26: 79-81.
34. Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013; 121: E90-E7.
35. Guo ST, Lin CM, Xu ZH, Miao L, Wang YH, Huang L. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. Acs Nano. 2014; 8: 4996-5009.